Switch theme
Sign up to access all valuation multiples
Qingdao Baheal Medical Inc is engaged in providing comprehensive marketing services for pharmaceutical product manufacturers.
2005
n/a
LTM Revenue $1.1B
LTM EBITDA $178M
$1.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Qingdao Baheal Medical has a last 12-month revenue of $1.1B and a last 12-month EBITDA of $178M.
In the most recent fiscal year, Qingdao Baheal Medical achieved revenue of $1.0B and an EBITDA of $136M.
Qingdao Baheal Medical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Qingdao Baheal Medical valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $1.0B | $1.1B | XXX | XXX | XXX |
| Gross Profit | $244M | $287M | XXX | XXX | XXX |
| Gross Margin | 23% | 26% | XXX | XXX | XXX |
| EBITDA | $136M | $168M | XXX | XXX | XXX |
| EBITDA Margin | 13% | 15% | XXX | XXX | XXX |
| Net Profit | $58.3M | $69.2M | XXX | XXX | XXX |
| Net Margin | 6% | 6% | XXX | XXX | XXX |
| Net Debt | n/a | $16.2M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Qingdao Baheal Medical's stock price is CNY 20 (or $3).
Qingdao Baheal Medical has current market cap of CNY 10.3B (or $1.4B), and EV of CNY 11.1B (or $1.5B).
See Qingdao Baheal Medical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.5B | $1.4B | XXX | XXX | XXX | XXX | $0.24 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Qingdao Baheal Medical has market cap of $1.4B and EV of $1.5B.
Qingdao Baheal Medical's trades at 1.4x LTM EV/Revenue multiple, and 8.6x LTM EBITDA.
Analysts estimate Qingdao Baheal Medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Qingdao Baheal Medical and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.5B | XXX | XXX | XXX |
| EV/Revenue | 1.4x | XXX | XXX | XXX |
| EV/EBITDA | 9.1x | XXX | XXX | XXX |
| P/E | 12.2x | XXX | XXX | XXX |
| P/E/Growth | 0.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpQingdao Baheal Medical's NTM/LTM revenue growth is 11%
Qingdao Baheal Medical's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Qingdao Baheal Medical's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Qingdao Baheal Medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Qingdao Baheal Medical and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 15% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 23% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 26% | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 10% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 0% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 18% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Alcidion Group | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Doctor Care Anywhere | XXX | XXX | XXX | XXX | XXX | XXX |
| Echo IQ | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Qingdao Baheal Medical acquired XXX companies to date.
Last acquisition by Qingdao Baheal Medical was XXXXXXXX, XXXXX XXXXX XXXXXX . Qingdao Baheal Medical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Qingdao Baheal Medical founded? | Qingdao Baheal Medical was founded in 2005. |
| Where is Qingdao Baheal Medical headquartered? | Qingdao Baheal Medical is headquartered in China. |
| Is Qingdao Baheal Medical publicy listed? | Yes, Qingdao Baheal Medical is a public company listed on SHE. |
| What is the stock symbol of Qingdao Baheal Medical? | Qingdao Baheal Medical trades under 301015 ticker. |
| When did Qingdao Baheal Medical go public? | Qingdao Baheal Medical went public in 2021. |
| Who are competitors of Qingdao Baheal Medical? | Similar companies to Qingdao Baheal Medical include e.g. Benevolent AI, Alcidion Group, CurveBeam AI, Doctor Care Anywhere. |
| What is the current market cap of Qingdao Baheal Medical? | Qingdao Baheal Medical's current market cap is $1.4B |
| What is the current revenue of Qingdao Baheal Medical? | Qingdao Baheal Medical's last 12-month revenue is $1.1B. |
| What is the current EBITDA of Qingdao Baheal Medical? | Qingdao Baheal Medical's last 12-month EBITDA is $178M. |
| What is the current EV/Revenue multiple of Qingdao Baheal Medical? | Current revenue multiple of Qingdao Baheal Medical is 1.4x. |
| What is the current EV/EBITDA multiple of Qingdao Baheal Medical? | Current EBITDA multiple of Qingdao Baheal Medical is 8.6x. |
| What is the current revenue growth of Qingdao Baheal Medical? | Qingdao Baheal Medical revenue growth between 2023 and 2024 was 5%. |
| Is Qingdao Baheal Medical profitable? | Yes, Qingdao Baheal Medical is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
